# US 2008/0269255 A1 · 4-Phenylpiperidine Derivatives as Renin Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269255 A1
- Document ID: US20080269255A1
- Status: Published application
- Kind: A1
- Application number: 12/163,038
- Filed: 2008-06-27
- Published: 2008-10-30
- Earliest claimed: 2003-11-26
- Assignees: Novartis AG
- Inventors: Richard Sedrani; Juergen Klaus Maibaum; Werner Breitenstein; Holger Sellner; Claus Ehrhardt; Nils Ostermann
- Web page: https://patentgrep.com/patent/US20080269255A1

## CPC

- C07D 401/10: linked by a carbon chain containing aromatic rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 13/12: of the kidneys
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/42: attached in position 3 or 5
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

## Claims

### Claim 1

A compound of the formula
wherein
R1 is —CH2—X, —O—X or —S(O)0-2—X; or
R1 is —NR—X, —NR8C(O)X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-(CH2)q—W in which
m, n and q are independently zero or an integer from 1 to 5;
p is zero or 1;
R9 and R10 are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or
R9 and R10 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH2—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen, halogen, cyano, hydroxy or lower alkoxy;
L is a bond; or
L is —(CH2)8—O—(CH2)v— in which
s and v are independently zero or an integer from 1 to 3; or
L is —C(O)—, —C(O)O—, —OC(O)—, —OC(O)NR12—, —NR12—, —NR13C(O)—, —NR13C(O)O— or —NR13C(O)NR12— in which
R12 and R13 are independently hydrogen or lower alkyl;
R3 is hydrogen, hydroxy, halogen or cyano provided that L is a bond; or
R3 is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or
R3 and R12 combined are alkylene which together with the nitrogen atom to which they are attached form a 5 to 6-membered ring;
R4 is hydrogen, optionally substituted lower alkyl or aryl;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R5 and R6 combined together with the carbon atoms to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided that R5 and R6 are attached to carbon atoms adjacent to each other; or
R5 and R6 combined are alkylene which together with the carbon atoms to which they are attached form a fused 5 to 7-membered ring provided that R5 and R6 are attached to carbon atoms adjacent to each other; or
C—R5 and C—R6 may be replaced with nitrogen;
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy, cycloalkyl, alkanoyl, alkyloxyalkoxy, alkanoyloxy, amino, alkylamino, dialkylamino, acylamino, carbamoyl, thiol, alkylthio, alkylthiono, sulfonyl, sulfonamido, sulfamoyl, nitro, cyano, carboxy, alkoxycarbonyl, aryl, alkenyl, alkynyl, aralkoxy, heterocyclyl including indolyl, imidazolyl, furyl, thienyl, thiazolyl, pyrrolidyl, pyridyl, pyrimidyl, piperidyl, morpholinyl and tetrazolyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2—, —O—CH2—, —CH2—O—, —S(O)0-2—CH2—, —CH2—S(O)0-2—, —NR14—CH2—, —CH2—NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′ position; or
C—R7 may be replaced with nitrogen;
Y is —(CH2)r—, —O—(CH2)r—, —(CH2)r—O—, —S0-2—(CH2)r— or —(CH2)r—S0-2— in which
r is zero or an integer from 1 to 3;
Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or
Q combined with the atoms to which it is attached form a 7- to 12-membered bicyclic aromatic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein
R1 is —CH2—X, —O—X or —S(O)2—X; or
R1 is —NR—X, —NR8C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-(CH2)q—W in which
m and n are independently zero or an integer from 1 to 5;
p is zero or 1;
q is zero;
R9 and R10 are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or
R9 and R10 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH2—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen, halogen, cyano, hydroxy or lower alkoxy;
L is a bond; or
L is —(CH2)s—O—(CH2)v— in which
s and v are zero; or
L is —C(O)—, —C(O)O—, —OC(O)—, —OC(O)NR12—, —NR12—, —NR13C(O)—, —NR13C(O)O— or —NR13C(O)NR12— in which
R12 and R13 are independently hydrogen or lower alkyl;
R3 is hydrogen, halogen or cyano provided that L is a bond; or
R3 is optionally substituted lower alkyl, aralkyl, heteroaralkyl, aryl or heterocyclyl; or
R3 and R12 combined are alkylene which together with the nitrogen atom to which they are attached form a 5- to 6-membered ring;
R4 is hydrogen, optionally substituted lower alkyl or aryl;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R5 and R6 combined together with the carbon atoms to which they are attached form a fused 5- to 6-membered aromatic or heteroaromatic ring provided that R5 and R6 are attached to carbon atoms adjacent to each other; or
R5 and R6 combined are alkylene which together with the carbon atoms to which they are attached form a fused 5- to 7-membered ring provided that R5 and R6 are attached to carbon atoms adjacent to each other; or
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted, lower alkyl, lower alkoxy or cycloalkyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2—, —O—CH2—, —CH2—O—, —S(O)0-2—CH2—, —CH2—S(O)0-2—, —NR14—CH2—, —CH2—NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′ position;
Y is —(CH2)r— in which
r is zero;
Q combined with the carbon atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or
Q combined with the carbon atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound according to claim 2 of the formula
wherein
R1, R2, L, R3, R4, R5, R6, R7 and Q have meanings as defined in claim 2;
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

A compound according to claim 2 of the formula
wherein
R1, R2, L, R3, R4, R5, R6, R7 and Q have meanings as defined in claim 2;
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

A compound according to claim 4 wherein
R1 is —CH2—X, —O—X or —S—X; or
R1 is —NR8—X, —NR8C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-W in which
m and n are independently zero or an integer of 1 or 2;
p is zero or 1;
R9 and R10 are independently hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or cycloalkyl; or
R9 and R10 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH2—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen, halogen or hydroxy;
L is a bond;
R3 is hydrogen or halogen;
R4 is hydrogen, optionally substituted lower alkyl or aryl;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2, —O—CH2—, —CH2—O—, —S(O)0-2—CH2—, —CH2—S(O)0-2—, —NR14—CH—, —CH—NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′-position;
Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or
Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

A compound according to claim 5 wherein
R1 is —CH2—X, —O—X or —S—X; or
R1 is —NR8—X, —NR8C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-W in which
m and n are independently zero or an integer of 1 or 2;
p is zero or 1;
R9 and R10 are independently hydrogen or lower alkyl; or
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH2—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen, halogen or hydroxy;
L is a bond;
R3 is hydrogen or halogen;
R4 is hydrogen;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2—, —O—CH2—, —CH2—O—, —S(O)0-2—CH2—, —CH2—S(O)0-2—, —NR14—CH2—, —CH2—NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′-position;
Q combined with the atoms to which it is attached form a 5- to 6-membered monocyclic aromatic or heteroaromatic ring; or
Q combined with the atoms to which it is attached form a 9- to 10-membered bicyclic aromatic or heterocyclic ring;
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

A compound according to claim 6 wherein
R1 is —NR8—X, —N % C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6)

A compound according to claim 6 wherein
Q combined with the carbon atoms to which it is attached form a pyridyl or pyrimidinyl ring;
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 6)

A compound according to claim 6 wherein
Q combined with the carbon atoms to which it is attached form a thienyl, furyl, pyrrolyl or indolyl ring;
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 5)

A compound according to claim 5 of the formula
wherein
R1 is —CH2—X, —O—X or —S—X; or
R1 is —NR—X, —NR8C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-W in which
m, n and p are independently zero or 1;
R9 is hydrogen;
R10 is hydrogen or lower alkyl;
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen;
R3 is hydrogen or halogen;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2—, —O—CH2—, —CH2—O—, —S(O)0-2—CH2—, —CH2—S(O)0-2—, —NR14—CH2—, —CH—NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′-position;
R15 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

A compound according to claim 10 wherein
R1 is —O—X or —S—X; and
X is —(CH2)m—(CR9R10)p—(CH2)n-Z-W in which
m is 1;
n and p are zero;
Z is a bond;
W is aryl or heterocyclyl;
R3 is hydrogen or halogen;
R5 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R6 is hydrogen;
R7 is hydrogen;
R15 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 11)

A compound according to claim 11 wherein
R3 is hydrogen;
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

A compound according to claim 12 wherein
W is monocyclic aryl;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 5)

A compound according to claim 5 wherein
p is 1;
R9 and R11 combined are alkylene which together with the carbon atom to which they are attached form a 3- to 6-membered ring;
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

A compound according to claim 14 of the formula
wherein
R1 is —CH2—X, —O—X or —S—X; or
R1 is —NR8—X, —NR8C(O)—X or —NR8S(O)2—X in which
R8 is hydrogen or lower alkyl; and
X is —(CH2), —CR9R10—(CH2)n-Z-W in which
m and n are 1;
Z is a bond; or
Z is O, S(O)0-2, or —NR11— in which
R11 is hydrogen or lower alkyl, provided that R1 is —CH2—X when m, n and p are all zero;
W is aryl or heterocyclyl;
R2 is hydrogen;
R3 is hydrogen or halogen;
R5 and R6 are independently hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R7 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl; or
R7 and R6 combined are O, S(O)0-2, —NR14—, —(CH2)1-2—, —O—CH═, —CH2—O—, —S(O)0-2—CH2—, —CH2S(O)0-2—, —NR14—CH2—, —CH2NR14—, —S(O)0-2—NR14— or —NR14—S(O)0-2— in which
R14 is hydrogen or lower alkyl, provided R6 is located at the 2′-position;
R15 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

A compound of claim 15 wherein
R1 is —O—X or —S—X; and
X is —CH2—CR9R10—CH2-Z-W in which
Z is a bond;
W is aryl;
R3 is hydrogen;
R5 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
R6 is hydrogen;
R7 is hydrogen;
R15 is hydrogen, halogen, hydroxy, trifluoromethyl, optionally substituted lower alkyl, lower alkoxy or cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method for the inhibition of renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 18 (depends on 1)

A method for the prevention and/or treatment of conditions associated with renin activity in mammals which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 19 (depends on 18)

A method according to claim 18, which method comprises administering said compound in combination with a therapeutically effective amount of an anti-diabetic agent, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.

### Claim 20 (depends on 1)

A method for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders, which method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with one or more pharmaceutically acceptable carriers.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a therapeutically effective amount of an anti-diabetic agents, a hypolipidemic agent, an anti-obesity agent or an anti-hypertensive agent.

### Claim 23 (depends on 21, 22)

A pharmaceutical composition according to claim 21 or 22 for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

### Claim 24 (depends on 21, 22)

A pharmaceutical composition according to claim 21 or 22, for use as medicament.

### Claim 25 (depends on 21, 22)

Use of a pharmaceutical composition according to claim 21 or 22, for the preparation of a medicament for the treatment of conditions associated with renin activity.

### Claim 26 (depends on 1)

Use of a compound according to claim 1, for the preparation of a pharmaceutical composition for the treatment of conditions associated with renin activity.

### Claim 27 (depends on 25, 26)

Use according to claim 25 or 26, wherein the condition associated with renin activity is selected from hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

### Claim 28 (depends on 1)

A compound according to claim 1, for use as a medicament.
